BlackRock Institutional Trust’s Alexion Pharmaceuticals ALXN Stock Holding History

BlackRock Institutional Trust’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$745M	Buy	6,089,611 +118,510	+2%	+$14.5M	0.11%	188
2016 Q3	$732M	Buy	5,971,101 +284,747	+5%	+$36.7M	0.11%	178
2016 Q2	$664M	Buy	5,686,354 +84,485	+2%	+$12M	0.11%	189
2016 Q1	$780M	Buy	5,601,869 +15,733	+0.3%	+$2.31M	0.13%	158
2015 Q4	$1.07B	Sell	5,586,136 -1,015	-0%	-$177K	0.18%	112
2015 Q3	$874M	Sell	5,587,151 -59,671	-1%	-$10.9M	0.15%	131
2015 Q2	$1.02B	Buy	5,646,822 +351,002	+7%	+$60.6M	0.16%	117
2015 Q1	$918M	Buy	5,295,820 +186,951	+4%	+$33.8M	0.14%	137
2014 Q4	$945M	Buy	5,108,869 +37,005	+0.7%	+$6.86M	0.15%	130
2014 Q3	$841M	Sell	5,071,864 -11,552	-0.2%	-$1.9M	0.14%	145
2014 Q2	$794M	Sell	5,083,416 -167,216	-3%	-$26.4M	0.13%	158
2014 Q1	$799M	Buy	5,250,632 +221,938	+4%	+$35.3M	0.14%	146
2013 Q4	$668M	Sell	5,028,694 -89,198	-2%	-$10.7M	0.12%	170
2013 Q3	$594M	Sell	5,117,892 -47,941	-0.9%	-$5.26M	0.11%	179
2013 Q2	$476M	Buy	+5,165,833	New	+$498M	0.1%	210

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BlackRock Institutional Trust's ALXN Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Alexion Pharmaceuticals (ALXN) stake by 2% in Q4 2016, buying an estimated $14.5M and bringing the position to 6,089,611 shares worth $745M. The position accounts for 0.11% of the portfolio, ranked #188.

BlackRock Institutional Trust first reported a position in ALXN in Q2 2013 and has held it in 15 quarters since. The position peaked at $1.07B in Q4 2015. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

BlackRock Institutional Trust held 6,089,611 shares of Alexion Pharmaceuticals worth $745M as of Q4 2016.
BlackRock Institutional Trust bought 118,510 Alexion Pharmaceuticals shares in Q4 2016, an estimated $14.5M.
Alexion Pharmaceuticals made up 0.11% of BlackRock Institutional Trust's portfolio in Q4 2016, its #188 holding.
BlackRock Institutional Trust first reported a position in Alexion Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
BlackRock Institutional Trust's Alexion Pharmaceuticals position peaked at $1.07B in Q4 2015.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.